Day One goes to the market for $150M as biotech kicks off NDA request for pediatric brain cancer drug
Day One Biopharmaceuticals will offer up more than 11.5 million shares to nab $150 million in gross proceeds after the biotech last month started a rolling submission for its pediatric brain cancer drug, which had a fresh data drop at last weekend’s ASCO.
The Brisbane, CA-based drug developer will also give investors a chance to buy another 1.73 million shares at the price of $13 apiece, which would send proceeds up another $22.5 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.